{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T22:10:12Z","timestamp":1723932612070},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,17]]},"DOI":"10.7759\/cureus.67091","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T21:37:15Z","timestamp":1723930635000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeting Apolipoprotein C-III for the Management of Severe Hypertriglyceridemia: Current Research and Future Directions"],"prefix":"10.7759","author":[{"given":"Mili","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abisheikh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Ayyad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Swartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyaal","family":"Jafrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhir","family":"Gala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan G","year":"2007","unstructured":"Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007, 176:1113-20. 10.1503\/cmaj.060963","journal-title":"CMAJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund L","year":"2012","unstructured":"Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012, 97:2969-89. 10.1210\/jc.2011-3213","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0825","article-title":"The diagnosis and treatment of hypertriglyceridemia","volume":"116","author":"Parhofer KG","year":"2019","unstructured":"Parhofer KG, Laufs U. The diagnosis and treatment of hypertriglyceridemia. Dtsch Arztebl Int. 2019, 116:825-32. 10.3238\/arztebl.2019.0825","journal-title":"Dtsch Arztebl Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Bor\u00e9n J","year":"2020","unstructured":"Bor\u00e9n J, Packard CJ, Taskinen MR. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne). 2020, 11:474. 10.3389\/fendo.2020.00474","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson M","year":"2013","unstructured":"Larsson M, Vorrsj\u00f6 E, Talmud P, Lookene A, Olivecrona G. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem. 2013, 288:33997-4008. 10.1074\/jbc.M113.495366","journal-title":"J Biol Chem"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-020-06071-5","article-title":"Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies","volume":"48","author":"Dib I","year":"2021","unstructured":"Dib I, Khalil A, Chouaib R, El-Makhour Y, Noureddine H. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies. Mol Biol Rep. 2021, 48:875-86. 10.1007\/s11033-020-06071-5","journal-title":"Mol Biol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-021-01531-8","article-title":"APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups","volume":"20","author":"Goyal S","year":"2021","unstructured":"Goyal S, Tanigawa Y, Zhang W, et al.. APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups. Lipids Health Dis. 2021, 20:113. 10.1186\/s12944-021-01531-8","journal-title":"Lipids Health Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-021-00962-z","article-title":"Clinical management of hypertriglyceridemia in the prevention of cardiovascular disease and pancreatitis","volume":"23","author":"Hernandez P","year":"2021","unstructured":"Hernandez P, Passi N, Modarressi T, et al.. Clinical management of hypertriglyceridemia in the prevention of cardiovascular disease and pancreatitis. Curr Atheroscler Rep. 2021, 23:72. 10.1007\/s11883-021-00962-z","journal-title":"Curr Atheroscler Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-020-00170-x","article-title":"Prevalence of US adults with triglycerides\u2009\u2265\u2009150\u00a0mg\/dl: NHANES 2007-2014","volume":"9","author":"Fan W","year":"2020","unstructured":"Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Prevalence of US adults with triglycerides\u2009\u2265\u2009150\u00a0mg\/dl: NHANES 2007-2014. Cardiol Ther. 2020, 9:207-13. 10.1007\/s40119-020-00170-x","journal-title":"Cardiol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-021-00939-y","article-title":"The genetic basis of hypertriglyceridemia","volume":"23","author":"Carrasquilla GD","year":"2021","unstructured":"Carrasquilla GD, Christiansen MR, Kilpel\u00e4inen TO. The genetic basis of hypertriglyceridemia. Curr Atheroscler Rep. 2021, 23:39. 10.1007\/s11883-021-00939-y","journal-title":"Curr Atheroscler Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/nu14051104","article-title":"The effect of dietary interventions on hypertriglyceridemia: from public health to molecular nutrition evidence","volume":"14","author":"Luna-Castillo KP","year":"2022","unstructured":"Luna-Castillo KP, Olivares-Ochoa XC, Hern\u00e1ndez-Ruiz RG, et al.. The effect of dietary interventions on hypertriglyceridemia: from public health to molecular nutrition evidence. Nutrients. 2022, 14:1104. 10.3390\/nu14051104","journal-title":"Nutrients"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5762395","article-title":"Lipid-induced mechanisms of metabolic syndrome","volume":"2020","author":"Denisenko YK","year":"2020","unstructured":"Denisenko YK, Kytikova OY, Novgorodtseva TP, Antonyuk MV, Gvozdenko TA, Kantur TA. Lipid-induced mechanisms of metabolic syndrome. J Obes. 2020, 2020:5762395. 10.1155\/2020\/5762395","journal-title":"J Obes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-2-55","article-title":"Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment","volume":"2","author":"Halpern A","year":"2010","unstructured":"Halpern A, Mancini MC, Magalh\u00e3es ME, et al.. Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment. Diabetol Metab Syndr. 2010, 2:55. 10.1186\/1758-5996-2-55","journal-title":"Diabetol Metab Syndr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2011.10.003","article-title":"Hypertriglyceridemia secondary to obesity and diabetes","volume":"1821","author":"Subramanian S","year":"2012","unstructured":"Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta. 2012, 1821:819-25. 10.1016\/j.bbalip.2011.10.003","journal-title":"Biochim Biophys Acta"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175660","article-title":"Sugar and dyslipidemia: a double-hit, perfect storm","volume":"12","author":"Gugliucci A","year":"2023","unstructured":"Gugliucci A. Sugar and dyslipidemia: a double-hit, perfect storm. J Clin Med. 2023, 12:5660. 10.3390\/jcm12175660","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X14666180123165542","article-title":"Hypertriglyceridemia - common causes, prevention and treatment strategies","volume":"14","author":"Rygiel K","year":"2018","unstructured":"Rygiel K. Hypertriglyceridemia - common causes, prevention and treatment strategies. Curr Cardiol Rev. 2018, 14:67-76. 10.2174\/1573403X14666180123165542","journal-title":"Curr Cardiol Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312797","article-title":"Hypothyroidism-associated dyslipidemia: potential molecular mechanisms leading to NAFLD","volume":"22","author":"Mavromati M","year":"2021","unstructured":"Mavromati M, Jornayvaz FR. Hypothyroidism-associated dyslipidemia: potential molecular mechanisms leading to NAFLD. Int J Mol Sci. 2021, 22:12797. 10.3390\/ijms222312797","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2174\/1874192401105010064","article-title":"Dyslipidaemia in rheumatological autoimmune diseases","volume":"5","author":"Toms TE","year":"2011","unstructured":"Toms TE, Panoulas VF, Kitas GD. Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J. 2011, 5:64-75. 10.2174\/1874192401105010064","journal-title":"Open Cardiovasc Med J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV17054","article-title":"Current diagnosis and management of primary chylomicronemia","volume":"28","author":"Okazaki H","year":"2021","unstructured":"Okazaki H, Gotoda T, Ogura M, et al.. Current diagnosis and management of primary chylomicronemia. J Atheroscler Thromb. 2021, 28:883-904. 10.5551\/jat.RV17054","journal-title":"J Atheroscler Thromb"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-016-0614-1","article-title":"Why Is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?","volume":"18","author":"Taskinen MR","year":"2016","unstructured":"Taskinen MR, Bor\u00e9n J. Why Is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?. Curr Atheroscler Rep. 2016, 18:59. 10.1007\/s11883-016-0614-1","journal-title":"Curr Atheroscler Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-023-01080-8","article-title":"APOC-III: a gatekeeper in controlling triglyceride metabolism","volume":"25","author":"Giammanco A","year":"2023","unstructured":"Giammanco A, Spina R, Cefal\u00f9 AB, Averna M. APOC-III: a gatekeeper in controlling triglyceride metabolism. Curr Atheroscler Rep. 2023, 25:67-76. 10.1007\/s11883-023-01080-8","journal-title":"Curr Atheroscler Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-002-0384-9","article-title":"Lipoprotein lipase: structure, function, regulation, and role in disease","volume":"80","author":"Mead JR","year":"2002","unstructured":"Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002, 80:753-69. 10.1007\/s00109-002-0384-9","journal-title":"J Mol Med (Berl)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48865","article-title":"Lipoproteins and their effects on the cardiovascular system","volume":"15","author":"Das P","year":"2023","unstructured":"Das P, Ingole N. Lipoproteins and their effects on the cardiovascular system. Cureus. 2023, 15:e48865. 10.7759\/cureus.48865","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.12.050","article-title":"Hepatic lipase, high density lipoproteins, and hypertriglyceridemia","volume":"178","author":"Chatterjee C","year":"2011","unstructured":"Chatterjee C, Sparks DL. Hepatic lipase, high density lipoproteins, and hypertriglyceridemia. Am J Pathol. 2011, 178:1429-33. 10.1016\/j.ajpath.2010.12.050","journal-title":"Am J Pathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal V","year":"2018","unstructured":"Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zu\u00f1iga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018, 17:122. 10.1186\/s12933-018-0762-4","journal-title":"Cardiovasc Diabetol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.10.013","article-title":"Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population","volume":"188","author":"Florez H","year":"2006","unstructured":"Florez H, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Castillo-Florez S, Lee D, Goldberg R. Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. Atherosclerosis. 2006, 188:134-41. 10.1016\/j.atherosclerosis.2005.10.013","journal-title":"Atherosclerosis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1838679","article-title":"Apolipoprotein CIII overexpression-induced hypertriglyceridemia increases nonalcoholic fatty liver disease in association with inflammation and cell death","volume":"2017","author":"Paiva AA","year":"2017","unstructured":"Paiva AA, Raposo HF, Wanschel AC, Nardelli TR, Oliveira HC. Apolipoprotein CIII overexpression-induced hypertriglyceridemia increases nonalcoholic fatty liver disease in association with inflammation and cell death. Oxid Med Cell Longev. 2017, 2017:1838679. 10.1155\/2017\/1838679","journal-title":"Oxid Med Cell Longev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24571","article-title":"Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance","volume":"54","author":"Lee HY","year":"2011","unstructured":"Lee HY, Birkenfeld AL, Jornayvaz FR, et al.. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology. 2011, 54:1650-60. 10.1002\/hep.24571","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1423849112","article-title":"Apolipoprotein CIII links islet insulin resistance to \u03b2-cell failure in diabetes","volume":"112","author":"\u00c5vall K","year":"2015","unstructured":"\u00c5vall K, Ali Y, Leibiger IB, et al.. Apolipoprotein CIII links islet insulin resistance to \u03b2-cell failure in diabetes. Proc Natl Acad Sci U S A. 2015, 112:E2611-9. 10.1073\/pnas.1423849112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby J","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, et al.. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014, 371:22-31. 10.1056\/NEJMoa1307095","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen AB","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014, 371:32-41. 10.1056\/NEJMoa1308027","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170609081612","article-title":"APOC-III antisense oligonucleotides: a new option for the treatment of hypertriglyceridemia","volume":"25","author":"Schmitz J","year":"2018","unstructured":"Schmitz J, Gouni-Berthold I. APOC-III antisense oligonucleotides: a new option for the treatment of hypertriglyceridemia. Curr Med Chem. 2018, 25:1567-76. 10.2174\/0929867324666170609081612","journal-title":"Curr Med Chem"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz321","article-title":"Targeting RNA to lower triglycerides: long strides from short molecules","volume":"40","author":"Qamar A","year":"2019","unstructured":"Qamar A, Libby P, Bhatt DL. Targeting RNA to lower triglycerides: long strides from short molecules. Eur Heart J. 2019, 40:2797-800. 10.1093\/eurheartj\/ehz321","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000136","article-title":"Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease","volume":"22","author":"Kohan AB","year":"2015","unstructured":"Kohan AB. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2015, 22:119-25. 10.1097\/MED.0000000000000136","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-019-0791-9","article-title":"Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD","volume":"21","author":"Taskinen MR","year":"2019","unstructured":"Taskinen MR, Packard CJ, Bor\u00e9n J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep. 2019, 21:27. 10.1007\/s11883-019-0791-9","journal-title":"Curr Atheroscler Rep"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-024-09893-x","article-title":"Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis","author":"Masson W","year":"2024","unstructured":"Masson W, Lobo M, Nogueira JP, Corral P, Barbagelata L, Siniawski D. Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2024, 10.1007\/s11154-024-09893-x","journal-title":"Rev Endocr Metab Disord"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel frontier in pharmacological strategy","volume":"14","author":"Collotta D","year":"2023","unstructured":"Collotta D, Bertocchi I, Chiapello E, Collino M. Antisense oligonucleotides: a novel frontier in pharmacological strategy. Front Pharmacol. 2023, 14:1304342. 10.3389\/fphar.2023.1304342","journal-title":"Front Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander VJ","year":"2019","unstructured":"Alexander VJ, Xia S, Hurh E, et al.. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019, 40:2785-96. 10.1093\/eurheartj\/ehz209","journal-title":"Eur Heart J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang XH","year":"2017","unstructured":"Liang XH, Sun H, Nichols JG, Crooke ST. RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017, 25:2075-92. 10.1016\/j.ymthe.2017.06.002","journal-title":"Mol Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole R","year":"2012","unstructured":"Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012, 11:125-40. 10.1038\/nrd3625","journal-title":"Nat Rev Drug Discov"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.14304\/surya.jpr.v4n7.5","article-title":"RNA therapeutics: RNAi and antisense mechanisms and clinical applications","volume":"4","author":"Chery J","year":"2016","unstructured":"Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J. 2016, 4:35-50. 10.14304\/surya.jpr.v4n7.5","journal-title":"Postdoc J"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold I","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, et al.. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021, 9:264-75. 10.1016\/S2213-8587(21)00046-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels\u00a0in familial chylomicronemia syndrome","volume":"381","author":"Witztum JL","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, et al.. Volanesorsen and triglyceride levels\u00a0in familial chylomicronemia syndrome. N Engl J Med. 2019, 381:531-42. 10.1056\/NEJMoa1715944","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00252","article-title":"Causes and consequences of hypertriglyceridemia","volume":"11","author":"Packard CJ","year":"2020","unstructured":"Packard CJ, Boren J, Taskinen MR. Causes and consequences of hypertriglyceridemia. Front Endocrinol (Lausanne). 2020, 11:252. 10.3389\/fendo.2020.00252","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134399","article-title":"Triglyceride-rich lipoprotein metabolism: key regulators of their flux","volume":"12","author":"Gugliucci A","year":"2023","unstructured":"Gugliucci A. Triglyceride-rich lipoprotein metabolism: key regulators of their flux. J Clin Med. 2023, 12:4399. 10.3390\/jcm12134399","journal-title":"J Clin Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.10.006","article-title":"Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes","volume":"15","author":"Buckner T","year":"2021","unstructured":"Buckner T, Shao B, Eckel RH, Heinecke JW, Bornfeldt KE, Snell-Bergeon J. Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes. J Clin Lipidol. 2021, 15:235-42. 10.1016\/j.jacl.2020.10.006","journal-title":"J Clin Lipidol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02822-w","article-title":"Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis","volume":"24","author":"Mart\u00edn-Gonz\u00e1lez C","year":"2022","unstructured":"Mart\u00edn-Gonz\u00e1lez C, Mart\u00edn-Folgueras T, Quevedo-Abeledo JC, et al.. Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis. Arthritis Res Ther. 2022, 24:126. 10.1186\/s13075-022-02822-w","journal-title":"Arthritis Res Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117545","article-title":"Modification of lipoprotein metabolism and function driving atherogenesis in diabetes","volume":"394","author":"Luciani L","year":"2024","unstructured":"Luciani L, Pedrelli M, Parini P. Modification of lipoprotein metabolism and function driving atherogenesis in diabetes. Atherosclerosis. 2024, 394:117545. 10.1016\/j.atherosclerosis.2024.117545","journal-title":"Atherosclerosis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019, 139:e1082-143. 10.1161\/CIR.0000000000000625","journal-title":"Circulation"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline","volume":"105","author":"Newman CB","year":"2020","unstructured":"Newman CB, Blaha MJ, Boord JB, et al.. Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2020, 105:3613-82. 10.1210\/clinem\/dgaa674","journal-title":"J Clin Endocrinol Metab"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-11-125","article-title":"Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction","volume":"11","author":"Tenenbaum A","year":"2012","unstructured":"Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012, 11:125. 10.1186\/1475-2840-11-125","journal-title":"Cardiovasc Diabetol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich AJ","year":"2022","unstructured":"Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022, 43:611-53. 10.1210\/endrev\/bnab037","journal-title":"Endocr Rev"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt DL","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al.. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019, 380:11-22. 10.1056\/NEJMoa1812792","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus","volume":"6","author":"Elam M","year":"2011","unstructured":"Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus. Clin Lipidol. 2011, 6:9-20. 10.2217\/clp.10.84","journal-title":"Clin Lipidol"},{"key":"ref55","article-title":"Lifestyle modifications for treatment of hypertriglyceridemia [Article in Japanese]","volume":"71","author":"Ohni M","year":"2013","unstructured":"Ohni M. Lifestyle modifications for treatment of hypertriglyceridemia [Article in Japanese]. Nihon Rinsho. 2013, 71:1630-5.","journal-title":"Nihon Rinsho"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2017.11.017","article-title":"Optimizing non-pharmacologic management of hypertriglyceridemia","volume":"48","author":"Byrne A","year":"2017","unstructured":"Byrne A, Makadia S, Sutherland A, Miller M. Optimizing non-pharmacologic management of hypertriglyceridemia. Arch Med Res. 2017, 48:483-7. 10.1016\/j.arcmed.2017.11.017","journal-title":"Arch Med Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.402","article-title":"Lipoprotein lipase: is it a magic target for the treatment of hypertriglyceridemia","volume":"37","author":"Moon JH","year":"2022","unstructured":"Moon JH, Kim K, Choi SH. Lipoprotein lipase: is it a magic target for the treatment of hypertriglyceridemia. Endocrinol Metab (Seoul). 2022, 37:575-86. 10.3803\/EnM.2022.402","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11236949","article-title":"A multi-center, prospective observational study to investigate the safety, compliance, and efficacy of omethyl QTlet soft capsule","volume":"11","author":"Ki YJ","year":"2022","unstructured":"Ki YJ, Han SJ, Cha TJ, et al.. A multi-center, prospective observational study to investigate the safety, compliance, and efficacy of omethyl QTlet soft capsule. J Clin Med. 2022, 11:6949. 10.3390\/jcm11236949","journal-title":"J Clin Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020459","article-title":"Monoclonal antibodies, gene silencing and gene editing (CRISPR) therapies for the treatment of hyperlipidemia-the future is here","volume":"15","author":"Hermel M","year":"2023","unstructured":"Hermel M, Lieberman M, Slipczuk L, Rana JS, Virani SS. Monoclonal antibodies, gene silencing and gene editing (CRISPR) therapies for the treatment of hyperlipidemia-the future is here. Pharmaceutics. 2023, 15:459. 10.3390\/pharmaceutics15020459","journal-title":"Pharmaceutics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/282830-targeting-apolipoprotein-c-iii-for-the-management-of-severe-hypertriglyceridemia-current-research-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T21:37:20Z","timestamp":1723930640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/282830-targeting-apolipoprotein-c-iii-for-the-management-of-severe-hypertriglyceridemia-current-research-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.67091","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2024,8,17]]}}}